drugset / Trial / NCT01281306

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306 ↗

Phase 2 Completed 910 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).

Timeline

Start
2011-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 400 mg —
Subject Sacubitril Small molecule 50 mg —
Subject Sacubitril Small molecule 100 mg —
Subject Sacubitril Small molecule 200 mg —
Subject Sacubitril Small molecule 400 mg —
Subject Valsartan Unknown 320 mg —

Indications